Uncover the potential of REGENERON PHARMACEUTICALS, an undervalued stock. NASDAQ:REGN maintains a strong financial position and offers an appealing valuation.
Even during a down period for the markets, Genpact has gone against the grain, climbing to $50.06. Its shares have yielded a 27.5% return over the last six months, beating the S&P 500 by 29.2%. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
President Trump will today announce the imposition of new tariffs, with the details being keenly awaited by markets and likely to cause significant volatility.
